Mohammad Luqman

Indonesian Institute of Sciences — ID

Medicine · Health Sciences

11h-index1.0kcitations32works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(17), T-cell and B-cell Immunology(10), Immunotherapy and Immune Responses(8), Glycosylation and Glycoproteins Research(8), Lymphoma Diagnosis and Treatment(7)

Publications32 total

The cloning of ESAT-6, EspC and Rv2029c genes obtained from an Indonesian tuberculosis-infected patient
IOP Conference Series Earth and Environmental Science·2023Open Access
HCD122, on human chronic lymphocytic leukemia cells The antileukemia activity of a human anti-CD40 antagonist antibody,
2013
Abstract DDT02-02: Preclinical development of LFA102, a highly potent and selective neutralizing antibody against the prolactin receptor
Cancer Research·2011
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Blood·2008· 103 citedOpen Access
Malignant tumors of the minor salivary glands in northern Pakistan
Hematology/Oncology and Stem Cell Therapy·2008· 7 citedOpen Access
HCD122, an Antagonist Human Anti-CD40 Monoclonal Antibody, Enhances Efficacy of CHOP in Tumor Xenograft Model of Human Diffuse Large B-Cell Lymphoma.
Blood·2007· 1 cited
Efficacy of an Antagonistic Anti-CD40 Monoclonal Antibody, HCD122 (CHIR-12.12), in Preclinical Models of Human Non-Hodgkin’s Lymphoma and Hodgkin’s Disease.
Blood·2006· 9 cited
CHIR-12.12, an Antagonist Anti-CD40 Antibody, Exhibits Greater ADCC Than Rituximab Against a Variety of Malignant B Cells: Evaluation of FcγRIIIa Polymorphism and ADCC Response.
Blood·2005· 4 cited
A Non-Internalizing Anti-CD40 Antibody, CHIR-12.12, Blocks CD40L-Induced Cytokine Production and Mediates Greater ADCC Than Rituximab in Primary CLL Cells.
Blood·2005· 1 cited
Human Antagonistic Anti-CD40 Antibody, CHIR-12.12, Inhibits CD40-Mediated Survival of Chronic Lymphocytic Leukemia B Cells Leading to Cellular Apoptosis.
Blood·2005· 1 cited
Antagonist Anti-CD40 Antibody, CHIR-12.12, Induces ADCC, Inhibits Tumor Growth, and Prolongs Survival in a Human Multiple Myeloma Xenograft Model.
Blood·2005· 6 cited
Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma
Cancer Research·2005· 160 cited
A Fully Human Antagonist Anti-CD40 Antibody Triggers Significant Antitumor Activity Against Human Multiple Myeloma.
Blood·2004· 1 cited
A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin’s Lymphoma.
Blood·2004· 8 cited
Antagonist Anti-CD40 Monoclonal Antibody, CHIR-12.12, Inhibits Growth of a Rituximab-Resistant NHL Xenograft Model and Achieves Synergistic Activity When Combined with Ineffective Rituximab.
Blood·2004· 3 cited
Antagonist Anti-CD40 Antibody CHIR-12.12 Causes Tumor Regression and Prolongs Survival in Multiple Myeloma Xenograft Models.
Blood·2004· 1 citedOpen Access
Safety Evaluation of an Fully Human Antagonist Anti-CD40 Antibody, CHIR-12.12, in a Dose Range-Finding Study in Cynomolgus Monkeys.
Blood·2004· 6 cited
In Vitro Activity of a Novel Fully Human Anti-CD40 Antibody CHIR-12.12 in Chronic Lymphocytic Leukemia: Blockade of CD40 Activation and Induction of ADCC.
Blood·2004· 12 citedOpen Access
Immunological Profile and Safety Evaluation in a 23-Week Single Dose Study in Cynomolgus Monkey with CHIR-12.12, a Fully Human Antagonist Anti-CD40 Antibody.
Blood·2004· 4 cited
Antigen-Specific T Cell Tolerance Down-Regulates Mast Cell Responses in Vivo
Cellular Immunology·2000· 26 cited
page 1 of 2Next →

Frequent Co-authors

Tong Xia(11), Bahija Jallal(8), Kim Bottomly(7), Sharon L. Aukerman(6), Natasha Aziz(5), Georgios Georgakis(4), Cheryl Goldbeck(4), William G. Wierda(4), Susan O’Brien(4), Montesa Patawaran(4), Simon R. Carding(3), Sha Klabunde(3), Karen Lin(3), Anu Cherukuri(3), Edward E. Kadel(3), Anas Younes(3), Wen‐Kai Weng(3), Ursula Jeffry(3), Julie Klinger(3), Laurence Greenbaum(2)